Received Jul 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | Y010372 | — |
| YF | YELLOW FEVER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UK134AA | — |
No additional AE/PQC reported.; Email received in email to case que on 6/17/2025 11:29 AM with a scanned document from SANOFI; This spontaneous report was received from other healthcare professional and refers to a 63-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), reconstituted with sterile diluent (MERCK STERILE DILUENT), administered for prophylaxis (dose, route of administration, anatomical site of injection, lot # and expiration date were not provided). On an unknown date (reported as two weeks after the patient received the MMR II vaccine), the patient was vaccinated with the yellow fever vaccine (trade name not provided), lot #UK134AA (dose, route of administration, anatomical site of injection, indication and expiration date were not reported) (Inappropriate administration interval between different vaccines). The patient did not experience any adverse effects from the vaccination (no adverse events). Follow up information has been received from the nurse on 27-JUN-2025. The patient was vaccinated on 15-APR-2025, with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (lot number Y010372 has been verified to be valid, expiration date reported as 05-JUN-2026). On that same day, he also received hepatitis B vaccine (recombinant) suspension for injection (RECOMBIVAX HB) (lot number Y018229, has been verified to be valid, expiration date reported as 31-MAY-2027), Pneumococcal vaccine conj 20v (other manufacturer) (lot number LJ5283, expiration date 31-MAY-2026), and Diphtheria vaccine toxoid (+) Pertussis vaccine acellular 5-component (+) Tetanus vaccine toxoid (TDAP) (other manufacturer) (lot number U8352AA, expiration date 31-DEC-2026). The vaccines were administered from a vaccine provider and vaccinated at public health clinic/hospital and purchased with private funds. The operator of device was a health professional. The adverse event was previously reported to health department and to manufacturer. Moreover, it was reported that the patient was aware that he will need to complete a blood test or receive a second yellow fever vaccine to ensure he have adequate immunity against yellow fever.; Sender's Comments: Priority : 5 , Is case serious : No , MNSC number : 02823591-02823541 , CLIC number : , ESTAR number : , IRMS number : 500UW00000dWnIlYAK|30062025230049|1867 , Central date : 2025-07-01 , Classification : DMC, Attachment description : NSC Call , Safety case number : 2297631 , MNSC case number : 02823591 , MNSC interaction number : 02823541 , Integration log UniqueID : 500UW00000dWnIlYAK|30062025230049|1867 , Service cloud CaseID : 500UW00000dWnIlYAK
Prevnar 20; ADACEL; Hepatitis B; Merck sterile diluent